$AORT

GREEN ANDREW M sold $18K of AORT

GREEN ANDREW M (SVP, Regulatory and Quality) sold 616 shares of ARTIVION, INC. (AORT) at $28.55 on 2026-08-14.

Original reporting
SEC EDGAR · GREEN ANDREW M
Published Aug 17, 2026, 7:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 7:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
medium confidence
Mentioned
$AORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The newest disclosed fact is the insider sale details (616 shares, $28.5490/share, total $17,586.18) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale and the lack of a 10b5-1 plan, but there is no accompanying operational or financial catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing does not indicate intent or future trading.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17 after-hours/late session; transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction filing for Artivion, Inc. (AORT).

Company-level read

Ticker impact

$AORTNeutralMedium confidence
Context

Artivion disclosed an insider open-market sale by SVP Regulatory and Quality Green Andrew M of 616 shares at $28.5490 on 2026-08-14.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 insider transactions are common and the article provides only sale size and price, with no accompanying company news, guidance, or regulatory/legal event.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a pre-arranged 10b5-1 plan could be interpreted by some traders as less routine, potentially increasing short-term scrutiny.

Key entities

  • ARTIVION, INC.

    Company whose insider transaction was reported on Form 4.

  • GREEN ANDREW M

    SVP, Regulatory and Quality who sold 616 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AORTMed

Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem

Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.

$AORTMed

Why Artivion (AORT) Stock Is Trading Up Today

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

$AORTMedAI 8/10

Artivion (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

$AORTMed

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.